Sugi Predict

Sugi Predict / Targets / HAT1

HAT1

Histone acetyltransferase type B catalytic subunit · O14929 · HAT1 on Sugi Atlas →

10,222 patent compounds predicted against HAT1, 5,041 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2302734 SCHEMBL2302734 0.43 13/20
SCHEMBL2074153 SCHEMBL2074153 0.38 13/20
SCHEMBL2301819 SCHEMBL2301819 0.49 11/20
SCHEMBL4426339 SCHEMBL4426339 0.48 11/20
SCHEMBL2305672 SCHEMBL2305672 0.45 10/20
SCHEMBL2300728 SCHEMBL2300728 0.37 10/20
SCHEMBL3576192 SCHEMBL3576192 0.41 9/20
SCHEMBL2303032 SCHEMBL2303032 0.47 8/20
SCHEMBL869420 SCHEMBL869420 0.45 8/20
SCHEMBL3574158 SCHEMBL3574158 0.43 8/20
SCHEMBL2540321 SCHEMBL2540321 0.43 7/20
SCHEMBL3274043 SCHEMBL3274043 0.41 7/20
SCHEMBL3188134 SCHEMBL3188134 0.44 6/20
Riboflavin Riboflavin (SCHEMBL7706) 1.00 4/20
Riboflavin Riboflavin (SCHEMBL7707) 1.00 4/20
SCHEMBL182061 SCHEMBL182061 1.00 4/20
SCHEMBL182062 SCHEMBL182062 1.00 4/20
Riboflavin Riboflavin (SCHEMBL297531) 1.00 4/20
Riboflavin Riboflavin (SCHEMBL341564) 1.00 4/20
Riboflavin Riboflavin (SCHEMBL2420598) 1.00 4/20

Clinical trials — most relevant to HAT1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Vorinostat in Children PHASE1/PHASE2COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) PHASE2COMPLETED
Voronistat in Pediatric Patients With Drug Resistant Epilepsy PHASE2UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a HAT1 binder may also engage these)

ProteinNameSimilarity
Q8BY71 — 1.000 Q8BY71 →
Q5M939 — 0.993 Q5M939 →
P11497 — 0.964 P11497 →
ACACA Acetyl-CoA carboxylase 1 0.963 landscape →
Q923S8 — 0.963 Q923S8 →
Q28559 — 0.962 Q28559 →
Q5SWU9 — 0.961 Q5SWU9 →
Q8IWV8 — 0.961 Q8IWV8 →
Q8R418 — 0.961 Q8R418 →
A0A974H8H3 — 0.960 A0A974H8H3 →
Q6TV19 — 0.960 Q6TV19 →
Q4R4U1 — 0.959 Q4R4U1 →
HELZ Probable helicase with zinc finger domain 0.959 landscape →
A0MQH0 — 0.959 A0MQH0 →
Q8IZH2 — 0.958 Q8IZH2 →
Q6DFV5 — 0.958 Q6DFV5 →
RO60 RNA-binding protein RO60 0.958 landscape →
Q80YV4 — 0.957 Q80YV4 →
P11029 — 0.957 P11029 →
Q96JJ3 — 0.957 Q96JJ3 →
Q8BHL5 — 0.957 Q8BHL5 →
Q6TUI4 — 0.956 Q6TUI4 →
NAA15 N-alpha-acetyltransferase 15, NatA auxiliary subunit 0.956 landscape →
A4QNE0 — 0.956 A4QNE0 →
Q5BJZ6 — 0.956 Q5BJZ6 →
Q80UM3 — 0.956 Q80UM3 →
SEC63 Translocation protein SEC63 homolog 0.955 landscape →
Q9TTS3 — 0.955 Q9TTS3 →
Q5RCC1 — 0.955 Q5RCC1 →
Q8BWQ6 — 0.954 Q8BWQ6 →